Ascent Group LLC Boosts Holdings in Bristol-Myers Squibb (NYSE:BMY)

Ascent Group LLC increased its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 37.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 44,469 shares of the biopharmaceutical company's stock after buying an additional 12,227 shares during the period. Ascent Group LLC's holdings in Bristol-Myers Squibb were worth $2,515,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BMY. Pinney & Scofield Inc. purchased a new stake in Bristol-Myers Squibb in the 4th quarter valued at $25,000. Fairway Wealth LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $28,000. Transce3nd LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $28,000. Comprehensive Financial Planning Inc. PA purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $34,000. Finally, Tacita Capital Inc acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at approximately $39,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Analyst Ratings Changes

A number of research firms have commented on BMY. Piper Sandler assumed coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price target on the stock. The Goldman Sachs Group restated a "neutral" rating and set a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Citigroup boosted their price target on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Bristol-Myers Squibb has an average rating of "Hold" and an average price target of $58.00.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction dated Friday, April 25th. The stock was acquired at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the acquisition, the executive vice president now owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.09% of the stock is owned by company insiders.

Bristol-Myers Squibb Stock Up 0.2%

Shares of Bristol-Myers Squibb stock traded up $0.09 during trading hours on Wednesday, hitting $46.98. The company had a trading volume of 12,420,520 shares, compared to its average volume of 13,140,393. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The company's 50-day moving average is $51.26 and its two-hundred day moving average is $55.60. The company has a market cap of $95.61 billion, a P/E ratio of -10.63, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the prior year, the firm posted ($4.40) earnings per share. Bristol-Myers Squibb's revenue for the quarter was down 5.6% on a year-over-year basis. Analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were paid a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 5.28%. Bristol-Myers Squibb's dividend payout ratio is presently 92.88%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.